A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection

Cytomegalovirus (CMV) Clinical Trial

Official title:
A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT)

Status Completed

Clinical Trial Summary

The main aim of the study is to check if treatment with maribavir can protect Japanese people against Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting side effects from it. Japanese recipients of a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) will take Maribavir tablets two times a day for 8 weeks in this study. During the study, participants will visit their study clinic 18 times as a maximum.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05137717
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	December 23, 2021
Completion date	June 27, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05319353` - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection	Phase 3
Completed	`NCT05571137` - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
Not yet recruiting	`NCT06243731` - A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Completed	`NCT05576805` - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
Not yet recruiting	`NCT06213974` - A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Completed	`NCT02775240` - Study of SHP620 (Maribavir) in Healthy Adults	Phase 1
Completed	`NCT01611974` - Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients	Phase 2
Completed	`NCT02931539` - Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir	Phase 3
Completed	`NCT02927067` - A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants	Phase 3